EN DE
Watch InBioGen Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

InBioGen Co Ltd (101140) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of InBioGen Co Ltd stock KRW 3,793, price KRW 4,880, that is 22.3% below the price, quality 45 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Cyclical KR · ISIN KR7101140002

IC InBioGen Co Ltd logo Thin data Nov 10, 2026

InBioGen Co Ltd

101140 · KO
Expensive, weak quality

Our calculation puts a fair price 22% below what the stock costs today.

Low debt
Quality 45/100
Mixed Growth (revenue YoY −10.6 %/yr in KRW)
Revenue last quarter 18% below a year ago.
Fair value 3,793 KRW · Overvalued
Loss-making · -22.5% net margin (FY2025)
Negative free cash flow
Trails peers (2/10)
Narrow moat 18/100
Thin data
Estimate⚠ Small free float
Watch InBioGen Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

14,650 KRW 467.00 KRW Fair Value 3,793 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 467.00 KRW – 14,650 KRW · fair‑value band 2,845 KRW – 4,741 KRW · the 4,880 KRW price screens above the 3,793 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow InBioGen Co in your weekly email

Every Wednesday you see whether InBioGen Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

INBIOGEN Co., Ltd. engages in the manufacture and distribution of footwear products in South Korea. It is also involved in distribution of wood pellets; kiosk; and food and beverage businesses.

Show moreShow less

The company was formerly known as BTONE CO.,Ltd. INBIOGEN Co., Ltd. was founded in 1949 and is headquartered in Seoul, South Korea.

Stock analysis

InBioGen Co Ltd (101140) currently trades at 4,880 KRW, while our estimate is 3,793 KRW, 22% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 2,845 KRW (bear) to 4,741 KRW (bull), the price of 4,880 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Consumer Cyclical sector.

Mixed Growth: Spin-off in 2023: revenue and profit before it include the divested business. Growth is measured afresh from 2023.

InBioGen Co Ltd reported revenue of 6.3B KRW in FY2025 versus 10.5B KRW in FY2021, a compound −12.0%/yr. Reported net income was −1.4B KRW in FY2025.

Key figures

Market cap 48.7B KRW (≈ $36.5M) Micro · P/S ratio 9.01 · EPS (TTM) −2,076 KRW · Net margin −22.5% · Return on equity −13.6% · Return on assets (EBIT) −3.5% (5-year average) · Operating margin −61.2% · Revenue (TTM) 5.1B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).

What moves the price

The share trades about 64% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Cyclical peers we cover trades at 30% fair-value upside, at −22%, 101140 screens richer than that median.

Fair Value

Bear 2,845 KRW Fair Value 3,793 KRW Bull 4,741 KRW
Price 4,880 KRW · Downside -22.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 69
Does it invest with discipline instead of growing at any price?
Low Volatility 36
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2023: revenue and profit before it include the divested business. Growth is measured afresh from 2023.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−53.0% (2020) → −68.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

101140 screens overvalued: fair value 22% below the price. Compare with NIKE, Inc →

Compare InBioGen Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Footwear & Accessories · 100 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −22.3% · Below median
Profitability
Return on assets −0.9% · Below median
Net margin (12 months) −22.5% · Bottom 25%
Operating margin (12 months) −61.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −18.4% · Bottom 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Footwear & Accessories median · lower = cheaper

P/B 0.31× · Cheapest 25%
P/S (12 months) 9.55× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)4 · sector 35
FUTURE (revenue growth)0 · sector 13
PAST (return on equity)0 · sector 21
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 58

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Footwear & Accessories stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zhejiang China Commodities City Group 600415 ¥12.20 ¥29.20 +139% vs 101140
Yue Yuen Industrial (Holdings) Limited 0551 HK$13.76 HK$31.66 +130% vs 101140
Deckers Outdoor Corporation DECK $89.79 $176.31 +96% vs 101140
Crocs, Inc CROX $159.66 $219.85 +38% vs 101140
Birkenstock Holding BIRK $37.27 $48.51 +30% vs 101140
Huali Industrial Group 300979 ¥39.55 ¥51.22 +30% vs 101140
NIKE, Inc NKE $38.67 $34.42 −11% vs 101140
PUMA SE PUM €27.19 €22.86 −16% vs 101140
On Holding ONON $34.70 $27.10 −22% vs 101140
adidas AG ADS €178.35 €126.17 −29% vs 101140

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

InBioGen Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "InBioGen Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/101140

Frequently asked questions

Is InBioGen Co Ltd (101140) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 3,793 KRW versus a price of 4,880 KRW, about 22% lower (overvalued).
What is the fair value of 101140?
Our estimate for InBioGen Co Ltd is 3,793 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 4,880 KRW.
What is the quality score of 101140?
InBioGen Co Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for InBioGen Co Ltd (101140)?
Our calculated price target is the estimate of 3,793 KRW (as of Nov 10, 2026). Cautious scenario 2,845 KRW, optimistic scenario 4,741 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the InBioGen Co Ltd stock forecast for 2026?
Our estimate puts fair value at 3,793 KRW, about 22% lower versus a price of 4,880 KRW (overvalued). Cautious scenario 2,845 KRW, optimistic scenario 4,741 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of InBioGen Co Ltd (101140)?
InBioGen Co Ltd reported trailing-twelve-month revenue of about 5.1B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of InBioGen Co Ltd (101140)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For InBioGen Co Ltd it is 3,793 KRW per share (as of Nov 10, 2026), against a price of 4,880 KRW.
Is InBioGen Co Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 101140 trades above its calculated fair value: price 4,880 KRW, fair value 3,793 KRW, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 101140?
No. The price is what the market pays today (4,880 KRW); the fair value is what the company's own numbers justify (3,793 KRW). For InBioGen Co Ltd the two are 1,087 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is InBioGen Co Ltd worth?
The market values InBioGen Co Ltd at about 48.7B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 4,880 KRW; our models calculate a fair value of 3,793 KRW per share.
What do the bullish and bearish scenarios say about 101140?
Our models span a range for InBioGen Co Ltd: cautious scenario 2,845 KRW, base 3,793 KRW, optimistic 4,741 KRW per share (as of Nov 10, 2026, price 4,880 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of InBioGen Co Ltd (101140)?
Balance-sheet figures for InBioGen Co Ltd (as of Nov 10, 2026): return on equity −13.6%, debt of 0.00 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 101140 from its 52-week high?
InBioGen Co Ltd trades at 4,880 KRW, about 64% below its 52-week high of 13,700 KRW and 9% above the low of 4,490 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 3,793 KRW is for.
Which stocks are comparable to InBioGen Co Ltd?
From the same area (Consumer Cyclical) we also value NIKE, Inc, adidas AG, On Holding, Deckers Outdoor Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is InBioGen Co Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 4,880 KRW, calculated fair value 3,793 KRW (−22%), Quality Score 45/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. InBioGen Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of InBioGen Co Ltd (101140)?
The closing price on Nov 10, 2026 was 4,880 KRW. Our estimate is 3,793 KRW, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with InBioGen Co Ltd right now?
The price sits above even our optimistic bull case (4,741 KRW). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of InBioGen Co Ltd

How large is the market capitalisation of InBioGen Co Ltd (101140)?
The market capitalisation of InBioGen Co Ltd is 48.7B KRW (≈ $36.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of InBioGen Co Ltd (101140)?
The price-to-sales ratio of InBioGen Co Ltd is 9.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of InBioGen Co Ltd (101140)?
Earnings per share at InBioGen Co Ltd are −2,076 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of InBioGen Co Ltd (101140)?
The net margin of InBioGen Co Ltd is −22.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of InBioGen Co Ltd (101140)?
The return on equity (ROE) of InBioGen Co Ltd is −13.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of InBioGen Co Ltd (101140)?
On an EBIT basis the return on assets of InBioGen Co Ltd is −3.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of InBioGen Co Ltd (101140)?
The operating margin of InBioGen Co Ltd is −61.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at InBioGen Co Ltd (101140)?
Revenue at InBioGen Co Ltd is growing −18.4% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at InBioGen Co Ltd (101140)?
Earnings per share at InBioGen Co Ltd are growing −76.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does InBioGen Co Ltd (101140) generate?
The free cash flow of InBioGen Co Ltd is −5.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does InBioGen Co Ltd (101140) carry?
The net debt of InBioGen Co Ltd is 1.5B KRW (fiscal year 2019). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch InBioGen Co Ltd in the live analysis

One click puts InBioGen Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.